Navigation Links
Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168

MENLO PARK, Calif., Jan. 16 /PRNewswire/ -- Cogentus Pharmaceuticals, Inc. today announced that dosing has begun in a clinical study to confirm the full antiplatelet activity of its novel combination medicine CGT-2168. CGT-2168 is a once-daily capsule that combines clopidogrel (currently marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis as Plavix(R)) with a gastroprotectant (omeprazole) to improve the gastrointestinal safety of antiplatelet therapy.


The crossover study (CG106) will characterize the pharmacodynamic effects of CGT-2168 compared with Plavix and will expand earlier findings of comparability. "In a previous clinical trial we demonstrated that the absorption of CGT-2168 is equivalent to that of Plavix, and that the omeprazole component within CGT-2168 does not interfere with the metabolism of the clopidogrel component," said Cogentus Chairman and Chief Executive Officer Mark A. Goldsmith, M.D., Ph.D.

An independent study published this week in the Journal of the American College of Cardiology showed that commercially available omeprazole significantly decreases the antiplatelet activity of Plavix when the two medicines are co-administered. "This finding is consistent with our own earlier clinical data that revealed an adverse drug interaction between Plavix and Prilosec(R) (marketed omeprazole), and may raise serious concerns for patients and practitioners," Dr. Goldsmith said. "However, these findings contrast with the properties we have observed with our unique formulation, CGT-2168. We expect the CG106 trial to confirm that CGT-2168 exhibits full antiplatelet activity and avoids the drug-drug interaction reported with the individual drugs on the market today."

Separately, Cogentus has begun COGENT-1, a global Phase 3 trial that will evaluate the clinical benefits of CGT-2168 with aspirin compared to Plavix with aspirin. COGENT stands for the Clopidogrel and the Optimization of Gastrointestinal Events Trial.

While antiplatelet therapy has been shown to be effective in preventing major cardiovascular events, it is associated with significant gastrointestinal side effects including bleeding, which can interrupt treatment, may require hospitalization or in some cases even result in death. A study recently published in the Annals of Internal Medicines concluded that the antiplatelet drugs aspirin and clopidogrel are, respectively, the third and fourth most common causes of U.S. emergency room visits by older adults experiencing adverse drug events.

"Because of potentially important safety and efficacy concerns surrounding antiplatelet therapy, Cogentus is investing significantly in completing the testing of our next-generation medicine that may provide patients and physicians with a treatment option that preserves the full cardiovascular benefits while minimizing potentially dangerous side effects," Dr. Goldsmith said.


Cogentus Pharmaceuticals, Inc., of Menlo Park, CA, is a privately held specialty pharmaceutical company founded in 2006. Cogentus ( is committed to becoming a premier developer of innovative, fixed-dose combination prescription medicines serving unmet medical needs that drive significant commercial opportunities.

Plavix(R) is a registered trademark of Sanofi-Aventis.

Prilosec(R) is a registered trademark of AstraZeneca AB.

SOURCE Cogentus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cogentus to Launch Phase III Program of Novel Combination Product Designed to Reduce Bleeding Side Effect of Antiplatelet Therapy
2. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. ( Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
(Date:12/1/2015)... 1, 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... pain, announced today that the company will present at the ... 1-3 at the Luxe Sunset Boulevard Hotel in ... of Relmada Therapeutics, will present on Thursday, December 3, at ... . Please register at least 10 minutes prior to ...
(Date:12/1/2015)... DIEGO , Dec. 1, 2015   MabVax ... drug development company, announces it has filed an Investigational ... Drug Administration (FDA) for the Company,s lead fully human ... to FDA acceptance, MabVax plans to initiate the Phase ... --> --> The planned Phase ...
(Date:12/1/2015)... 1, 2015   Craneware, Inc ., the ... today announced the company will showcase a new ... ® solution at the American Society for ... . The new features are focused on simplifying ... and managing enterprise-wide pharmacy charges to ensure compliance ...
Breaking Medicine Technology:
(Date:12/1/2015)... Diego, CA (PRWEB) , ... December 01, 2015 ... ... and scale , Visage Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro ... mobile imaging results enhancements at the Radiological Society of North America (RSNA) 2015 ...
(Date:12/1/2015)... ... December 01, 2015 , ... McLean, VA., ... awarded a fixed price per sprint agile development contract to support the National ... over five years, provides software engineering, infrastructure, as well as operations and sustainment ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s latest white paper, ... addresses a main “pain point” for merging or aligning healthcare provider organizations—when mergers ... is signed. This quick-read guidance suggests that failing to recognize the power ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... With ... footage, and with full control over customization, the possibilities are truly endless, all with ... position randomization, overlay depth position, vertical flip, horizontal flip, depth of field and more, ...
(Date:12/1/2015)... ... December 01, 2015 , ... SonaCare Medical congratulates the University ... Innovation Award on November 18th. This prestigious award recognizes annually organizations that cultivate ... to the medical landscape. , The UCLH team won the award for their ...
Breaking Medicine News(10 mins):